Offer closed7 Nov 2016 15:04
, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, today announced the closing of its public offering of an aggregate of 2,424,242 unit etc.
"Public offering" that was not open to the public and particularly to its long-suffering investors.